Lawrence Scahill1, Sangchoon Jeon2, Susan J Boorin2, Christopher J McDougle3, Michael G Aman4, James Dziura5, James T McCracken6, Sonia Caprio5, L Eugene Arnold4, Ginger Nicol7, Yanhong Deng8, Saankari A Challa9, Benedetto Vitiello10. 1. Emory University School of Medicine and Marcus Autism Center, Atlanta. Electronic address: lawrence.scahill@emory.edu. 2. Yale University School of Nursing, West Haven, CT. 3. Harvard Medical School, Massachusetts General Hospital, and Lurie Center for Autism, Boston. 4. Nisonger Center, Ohio State University, Columbus. 5. Yale School of Medicine, New Haven, CT. 6. Division of Child Psychiatry, University of California, Los Angeles. 7. Washington University, St. Louis. 8. Yale University. 9. Emory University School of Medicine. 10. National Institute of Mental Health (NIMH), Bethesda, MD.
Abstract
OBJECTIVE: We examine weight gain and metabolic consequences of risperidone monotherapy in children with autism spectrum disorder (ASD). METHOD: This was a 24-week, multisite, randomized trial of risperidone only versus risperidone plus parent training in 124 children (mean age 6.9 ±2.35 years; 105 boys and 19 girls) with ASD and serious behavioral problems. We monitored height, weight, waist circumference, and adverse effects during the trial. Fasting blood samples were obtained before treatment and at week 16. RESULTS: In 97 children with a mean of 22.9 ± 2.8 weeks of risperidone exposure, there was a 5.4 ± 3.4 kg weight gain over 24 weeks (p < .0001); waist circumference increased from 60.7 ± 10.4 cm to 66.8 ± 11.3 cm (p < .0001). At baseline, 59 of 97 children (60.8%) were classified as having normal weight; by week 24, only 25 of 85 (29.4%) remained in that group. Growth curve analysis showed a significant change in body mass index (BMI) z scores from pretreatment to week 24 (p < .0001). This effect was significantly greater for children with reported increased appetite in the first 8 weeks. From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001). Adiponectin declined (p = .003). At baseline, 7 children met conventional criteria for metabolic syndrome; by week 16, 12 additional children were so classified. CONCLUSION: Rapid weight gain with risperidone treatment may promote the cascade of biochemical indices associated with insulin resistance and metabolic syndrome. Appetite, weight, waist circumference, liver function tests, blood lipids, and glucose warrant monitoring. Clinical trial registration information-Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders; http://clinicaltrials.gov/; NCT00080145. Published by Elsevier Inc.
RCT Entities:
OBJECTIVE: We examine weight gain and metabolic consequences of risperidone monotherapy in children with autism spectrum disorder (ASD). METHOD: This was a 24-week, multisite, randomized trial of risperidone only versus risperidone plus parent training in 124 children (mean age 6.9 ± 2.35 years; 105 boys and 19 girls) with ASD and serious behavioral problems. We monitored height, weight, waist circumference, and adverse effects during the trial. Fasting blood samples were obtained before treatment and at week 16. RESULTS: In 97 children with a mean of 22.9 ± 2.8 weeks of risperidone exposure, there was a 5.4 ± 3.4 kg weight gain over 24 weeks (p < .0001); waist circumference increased from 60.7 ± 10.4 cm to 66.8 ± 11.3 cm (p < .0001). At baseline, 59 of 97 children (60.8%) were classified as having normal weight; by week 24, only 25 of 85 (29.4%) remained in that group. Growth curve analysis showed a significant change in body mass index (BMI) z scores from pretreatment to week 24 (p < .0001). This effect was significantly greater for children with reported increased appetite in the first 8 weeks. From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001). Adiponectin declined (p = .003). At baseline, 7 children met conventional criteria for metabolic syndrome; by week 16, 12 additional children were so classified. CONCLUSION: Rapid weight gain with risperidone treatment may promote the cascade of biochemical indices associated with insulin resistance and metabolic syndrome. Appetite, weight, waist circumference, liver function tests, blood lipids, and glucose warrant monitoring. Clinical trial registration information-Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders; http://clinicaltrials.gov/; NCT00080145. Published by Elsevier Inc.
Authors: Howard Demb; Maria Valicenti-McDermott; Abegail Navarro; Keith Thomas Ayoob Journal: J Clin Psychopharmacol Date: 2011-10 Impact factor: 3.153
Authors: Celso Arango; Miriam Giráldez; Jessica Merchán-Naranjo; Inmaculada Baeza; Josefina Castro-Fornieles; Jose-Angel Alda; Carmen Martínez-Cantarero; Carmen Moreno; Pilar de Andrés; Cristina Cuerda; Elena de la Serna; Christoph U Correll; David Fraguas; Mara Parellada Journal: J Am Acad Child Adolesc Psychiatry Date: 2014-09-02 Impact factor: 8.829
Authors: Kyle Morrow; Keith A Young; Shawn Spencer; Edgar Samuel Medina; Michaela A Marziale; Alejandro Sanchez; James A Bourgeois Journal: Proc (Bayl Univ Med Cent) Date: 2020-10-06
Authors: Susan E Levy; Jennifer A Pinto-Martin; Chyrise B Bradley; Jesse Chittams; Susan L Johnson; Juhi Pandey; Alison Pomykacz; AnnJosette Ramirez; Ann Reynolds; Eric Rubenstein; Laura A Schieve; Stuart K Shapira; Aleda Thompson; Lisa Young; Tanja V E Kral Journal: J Pediatr Date: 2018-10-09 Impact factor: 4.406
Authors: Kristen K Criado; William G Sharp; Courtney E McCracken; Oana De Vinck-Baroody; Liansai Dong; Michael G Aman; Christopher J McDougle; James T McCracken; L Eugene Arnold; Carol Weitzman; John M Leventhal; Benedetto Vitiello; Lawrence Scahill Journal: Autism Date: 2017-03-22
Authors: Valentina Postorino; William G Sharp; Courtney E McCracken; Karen Bearss; T Lindsey Burrell; A Nichole Evans; Lawrence Scahill Journal: Clin Child Fam Psychol Rev Date: 2017-12
Authors: Lan Chi Vo; Christopher Snyder; Courtney McCracken; Christopher J McDougle; James T McCracken; Michael G Aman; Elaine Tierney; L Eugene Arnold; Daniel Levi; Michael Kelleman; Deirdre Carroll; John Morrissey; Benedetto Vitiello; Lawrence Scahill Journal: J Child Adolesc Psychopharmacol Date: 2016-10-11 Impact factor: 2.576
Authors: Laura C Politte; Lawrence Scahill; Janet Figueroa; James T McCracken; Bryan King; Christopher J McDougle Journal: Neuropsychopharmacology Date: 2018-02-27 Impact factor: 7.853
Authors: Shayleigh Dickson Page; Margaret C Souders; Tanja V E Kral; Ariana M Chao; Jennifer Pinto-Martin Journal: J Autism Dev Disord Date: 2021-03-05